Featured Research

from universities, journals, and other organizations

Common antibiotic helps lethal lung disease

Date:
August 29, 2011
Source:
University of California - San Francisco
Summary:
A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large new study.

A common antibiotic can help reduce the severe wheezing and other acute symptoms of chronic obstructive pulmonary disease, according to a large, multicenter clinical trial sponsored by the National Institutes of Health and conducted at the University of California, San Francisco (UCSF).

Related Articles


The study appears in the August 25 New England Journal of Medicine.

Chronic obstructive pulmonary disease, or COPD, is the third leading cause of death in the United States, surpassing strokes in 2008 -- heart disease and cancer are the top killers. It affects more than 12 million people in the United States. Worldwide, it is the fourth leading cause of death.

"This is a terrible disease that destroys the patient's lung function,'' said co-author Stephen C. Lazarus, a UCSF professor of medicine and chairman of the steering committee of the National Institutes of Health-funded network that conducted the study. "People with it become short of breath doing routine daily activities. For those with severe disease, it's like suffocating.

"This study suggests that regular use of a commonly prescribed antibiotic can reduce the frequency of exacerbations in the disease,'' he said.

Flare-ups, or exacerbations, are to COPD what heart attacks are to coronary artery disease: acute manifestations of a chronic disease that often hasten the progressive deterioration of the patient. The exacerbations are responsible for many doctor visits, trips to the emergency room and hospitalizations. Patients with acute exacerbations have a more rapid decline in lung function and a higher risk of death.

In the United States, most cases of the disease are due to smoking. In undeveloped countries, the illness is largely caused by biomass fuels, which are often used for heating and cooking indoors without a chimney.

The medical community both in the United States and worldwide has long been puzzled about how best to treat COPD. The antibiotic azithromycin -- already widely prescribed for numerous bacterial infections including pneumonia and strep throat -- is often given for flare-ups, generally for 5 to 10 days.

The NIH study was designed to examine whether that antibiotic would be effective in reducing COPD flare-ups. The trial involved 1,142 randomized participants from 17 medical sites who were at least 40 years old, had a clinical diagnosis of COPD, and had smoked for at least 10 years. The trial subjects received either azithromycin or a placebo daily for one year in addition to their usual care.

Those receiving azithromycin were 27% less likely to experience an acute flare-up which occurred after 266 days on median, compared to 174 days for those receiving the placebo. Patients taking the antibiotic also responded more favorably on questionnaires that asked them to assess their breathing ability and their general well-being.

"If we can improve the quality of life for patients with this disease and slow their loss of lung function, then we have done something really important for them,'' said Lazarus.

The researchers noted a side effect of adding the antibiotic to the usual treatment regimen: a small percentage of the patients suffered slight hearing loss.

Prescott G. Woodruff, MD, MPH, a UCSF associate professor of medicine and associate director of the UCSF Airway Clinical Research Center, is also a co-author of the study.

Scientists in the UCSF Pulmonary & Critical Care Division have been working for decades on basic and clinical research to learn more about chronic obstructive pulmonary disease and to devise new treatment approaches. They are currently recruiting for another study to see if a drug commonly used to reduce cholesterol is effective at preventing COPD flare-ups.

The new COPD study was supported by grants from the National Heart, Lung, and Blood Institute of the National Institutes of Health; the COPD Clinical Research Network is supported by the Division of Lung Diseases of the NHLBI. The study was carried out by the COPD Clinical Research Network, a consortium of research centers funded by the National Heart, Lung, and Blood Institute.


Story Source:

The above story is based on materials provided by University of California - San Francisco. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard K. Albert, John Connett, William C. Bailey, Richard Casaburi, J. Allen D. Cooper, Gerard J. Criner, Jeffrey L. Curtis, Mark T. Dransfield, MeiLan K. Han, Stephen C. Lazarus, Barry Make, Nathaniel Marchetti, Fernando J. Martinez, Nancy E. Madinger, Charlene McEvoy, Dennis E. Niewoehner, Janos Porsasz, Connie S. Price, John Reilly, Paul D. Scanlon, Frank C. Sciurba, Steven M. Scharf, George R. Washko, Prescott G. Woodruff, Nicholas R. Anthonisen. Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011; 365 (8): 689 DOI: 10.1056/NEJMoa1104623

Cite This Page:

University of California - San Francisco. "Common antibiotic helps lethal lung disease." ScienceDaily. ScienceDaily, 29 August 2011. <www.sciencedaily.com/releases/2011/08/110829115429.htm>.
University of California - San Francisco. (2011, August 29). Common antibiotic helps lethal lung disease. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2011/08/110829115429.htm
University of California - San Francisco. "Common antibiotic helps lethal lung disease." ScienceDaily. www.sciencedaily.com/releases/2011/08/110829115429.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Commonly Prescribed Antibiotic Reduces Acute COPD Attacks; Study Finds Azithromycin Lowers Frequency and Severity of Flare-Ups

Aug. 24, 2011 Adding a common antibiotic to the usual daily treatment regimen for chronic obstructive pulmonary disease (COPD) can reduce the occurrence of acute exacerbations and improve quality of life, reports ... read more

Novel Approach to Acute COPD Illness

Sep. 6, 2011 A new study that should help improve the condition for millions of individuals who suffer from chronic obstructive pulmonary disease (COPD). The study reveals that adding a common antibiotic - ... read more

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins